Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)- piperidine inhibitors of farnesyl-protein transferase: Design and synthesis of in vivo active antitumor compounds

Journal of Medicinal Chemistry

Volumn 40, Issue 26, 1997, Pages 4290-4301

  George Njoroge, F ^a   Vibulbhan, Bancha ^a   Rane, Dinananth F ^a   Robert Bishop, W ^a   Petrin, Joanne ^a   Patton, Robert ^a   Bryant, Mathew S ^a   Chen, K J ^a   Nomeir, Amin A ^a   Lin, C C ^a   Liu, Ming ^a   King, Ivan ^a   Chen, Jianping ^a   Lee, Suining ^a   Yaremko, Bohdan ^a   Dell, Janet ^a   Lipari, Philip ^a   Malkowski, Michael ^a   Li, Zujun ^a   Catino, Joseph ^a   Doll, Ronald J ^a   Girijavallabhan, V ^a   Ganguly, Ashit K ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 4 (3 BROMO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2B]PYRIDIN 11 YLIDENE) 1 (4 PYRIDINYLACETYL)PIPERIDINE; 4 (3 BROMO 8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2B]PYRIDIN 11 YLIDENE) 1 (4 PYRIDINYLACETYL)PIPERIDINE N1 OXIDE; 4 (3,8 DICHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2B]PYRIDIN 11 YLIDENE) 1 (4 PYRIDINYLACETYL)PIPERIDINE; 4 (8 CHLORO 3 IODO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2B]PYRIDIN 11 YLIDENE) 1 (4 PYRIDINYLACETYL)PIPERIDINE; 4 (8 CHLORO 5,6 DIHYDRO 3 METHYL 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE) 1 (4 PYRIDYLACETYL)PIPERIDINE; AGAR; DRUG VEHICLE; GERANYLTRANSFERASE; PIPERIDINE DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN 3T3; CELL STRAIN COS1; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; NUDE MOUSE; ONCOGENE H RAS; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; COS CELLS; DRUG DESIGN; ENZYME INHIBITORS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; PIPERIDINES; PROTEIN ISOPRENYLATION; PYRIDINES; RAS PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 6844259851     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970464g     Document Type: Article

References (27)

1. Mutt, V. Cholecystokinin: Isolation, Structure and Functions. In Gastrointestinal Hormones; Glass, G. B. J., Ed.; Raven Press: New York, 1980; pp 169-221.
2. Vanderhaeghen, J. J.; Crawley, J. N. Neuronal Cholecystokinin. Ann. N.Y. Acad. Sci. 1985, 448.
3. Crawley, J. N.; Corwin, R. L. Biological Actions of Cholecystokinin. Peptides 1994, 15, 731-755.
4. Dourish, C., T.; Hill, D. R. Classification and Function of CCK Receptors. Trends Pharmacol. Sci. 1987, 8, 207-208.
5. Smith, G. P.; Gibbs, J. Satiating Effect of Cholecystokinin. Ann. N.Y. Acad. Sci. 1994, 713, 236-241.
6. Raybould, H. E.; Lloyd, K. C. Integration of Postprandial Function in the Proximal Gastrointestinal Tract. Role of CCK and Sensory Pathways. Ann. N.Y. Acad. Sci. 1994, 713, 143-156.
7. Gibbs, J.; Young, R. C.; Smith, G. P. Cholecystokinin Decreased Food Intake in Rats. J. Comp. Physiol. Psychol. 1973, 84, 488-495.
8. Baile, C. A.; McLaughlin, C. L.; Della-Fera, M. A. Role of Cholecystokinin and Opioid Peptides in Control of Food Intake. Physiol. Rev. 1986, 66, 172-230.
9. Kissileff, H. R.; Pi-Sunyer, X.; Thornton, J.; Smith, G. P. C-terminal Octapeptide of Cholecystokinin Decrease Food Intake In Man. Am. J. Clin. Nutr. 1981, 34, 154-160.
10. Simmons, R. D.; Blossser, J. C.; Rosamond, J. D. FPL 14294: A Novel CCK-8 Agonist with Potent Intranasal Anorectic Activity in the Rat. Pharmacol. Biochem. Behav. 1994, 47, 701-708.
11. Schneider, L. H.; Murphy, R. B.; Gibbs, J.; Smith, G. P. Comparative Potencies of CCK Antagonist for the Reversal of the Satiating Effect of Cholecystokinin. In Cholecystokinin Antagonist; Wang, R. Y., Schoenfeld, R., Eds.; A. R. Liss: New York, 1988; pp 263-284.
12. Nadzan, A. M.; Kerwin, J. F., Jr. Cholecystokinin Agonists and Antagonists. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic: San Diego, CA, 1991; pp 191-200.
13. Shiosaki, K; Lin, C. W.; Kopecka, H.; Tufano, M. D.; Bianchi, B. R.; Miller, T. R.; Witte, D. G.; Nadzan, A. M. Boc-CCK-4 Derivatives Containing Side-Chain Ureas as Potent and Selective CCK-A Receptor Agonist. J. Med. Chem. 1991, 34, 2837-2842.
14. Holladay, M. W.; Bennett, M.; Tufano, M.; Lin, C.; Asin, K.; Witte, D.; Miller, T.; Bianchi, B.; Bednarz, L.; Nadzan, A. Synthesis and Biological Activities of CCK Heptapeptide Analogues. Effects on Conformational Constraints and Standard Modifications on Receptor Subtype Selectivity and Functional Activity in Vitro and Appetite Suppression In Vivo. J. Med. Chem. 1992, 35, 2919-2928.
15. 32. J. Med. Chem. 1992, 35, 4249-4252.
16. Rosamond, J. D.; Comstock, J.; Blosser, J. C.; Augello-Vaisey, S. J. Structural Requirements for Satiety Effect of CCK-8. In Peptides: Structure and Function; Deber, C. M., Hruby, V. J., Kopple, K. D., Eds.; Pierce: Rockford, IL, 1985; pp 241-244.
17. Simmons, R. D.; Pierson, M. E.; Kaiser, F.; Rosamond, J. D. ARL 15849: A Selective CCK-A Agonist with Anorectic Activity in the Rat and Dog. Pharmacol. Biochem. Behav., in press.
18. Albericio, F.; Kneib-Cordonier, N.; Lajos, G.; Hammer, R.; Hudson, D.; Barney, G. Solid-Phase Synthesis of C-terminal Peptide Amides Under Mild Conditions. In Peptides Chemistry and Biology, Proceedings of the Tenth American Peptide Symposium; Marshall, G. R., Ed.; Escom: Leiden, 1988; pp 159-161.
19. King, D. S.; Fields, C. G.; Fields, G. B. A Cleavage Method Which Minimizes Side Reactions Following Fmoc Solid-Phase Peptide Synthesis. Int. J. Pept. Protein Res. 1990, 36, 255-266.
20. 3H-(±)-L-364,718: A New Potent, Nonpeptide Cholecystokinin Antagonist Radioligand Selective for Peripheral Receptors. Mol. Pharmacol. 1986, 30, 212-217.
21. Chang, R. S. L.; Lotti, V. J. Biochemical and Pharmacological Characterization of an Extremely Potent and Selective Nonpeptide Cholecystokinin Antagonist. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 4923-4926.
22. Cox, R. H.; Maickel, R. P. Comparison of Anorexigenic and Behavioral Potency of Phenylethylamines. J. Pharmacol. Exp. Ther. 1972, 181, 1-9.
23. Holladay, M. W.; Kopecka, H.; Miller, T. R.; Bednarz, L.; Nikkel, A. L.; Bianchi, B. R.; Witte, D. G.; Shiosaki, K.; Lin, C. W.; Asin, K. E.; Nadzan, A. M. Teterapeptide CCK-A Agonists: Effects of Backbone N-Methylation on In Vitro and In Vivo CCK Activity. J. Med. Chem. 1994, 37, 630-635.
24. Billington, C. J.; Levine, A. S.; Morley, J. E. Are Peptides Truly Satiety Agents? A Method of Testing for Neurohumoral Satiety Effects. Am. J. Physiol. 1983, 245, R920-R926.
25. Lin, C.; Holladay, M. W.; Witte, D.; Miller, T.; Wolfram, C.; Bianchi, B. R.; Bennett, M.; Nadzan, A. A71378: A CCK Agonist with High Potency and Selectivity for CCK-A Receptors. Am. J. Physiol. 1990, 258, G648-651.
26. Peptide nomenclature follows the guidelines of the IUPAC-IUB Joint Commission on Biochemical Nomenclature. Eur. J. Biochem. 1984, 138, 9-37.
27. Hankovszky, O. H.; Hideg, K.; Bódi, I.; Frank, L. New Antiarrhythmic Agents. 2,2,5,5-Tetramethyl-3-pyrroline-3-carboxamides and 2,2,5,5-Tetramethylpyrrolidine-3-carboxamides. J. Med. Chem. 1986, 29, 1138-1152.